Azathioprine News and Research

RSS
Azathioprine is an immunosupressant used in organ transplantation, autoimmune disease such as rheumatoid arthritis or inflammatory bowel disease such as Crohn's disease and ulcerative colitis. It is a pro-drug, converted in the body to the active metabolites 6-mercaptopurine and 6-thioinosinic acid.
Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

No single immunosuppressive medication increases cancer risk in kidney transplant recipients

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Infliximab-azathioprine combination helps more Crohn's disease patients achieve remission

Infliximab-azathioprine combination helps more Crohn's disease patients achieve remission

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

Data on ULORIC treatment for gout flares presented at the 73rd American College of Rheumatology meeting

Data on ULORIC treatment for gout flares presented at the 73rd American College of Rheumatology meeting

CONFIRMS trial demonstrates efficacy of ULORIC for treating hyperuricemia in patients with gout

CONFIRMS trial demonstrates efficacy of ULORIC for treating hyperuricemia in patients with gout

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.